C-type lectins, fungi and Th17 responses  by Vautier, Simon et al.
Cytokine & Growth Factor Reviews 21 (2010) 405–412C-type lectins, fungi and Th17 responses
Simon Vautier, Maria da Glo´ria Sousa, Gordon D. Brown *
Aberdeen Fungal Group, Section of Infection and Immunity, Institute of Medical Sciences, School of Medicine and Dentistry, University of Aberdeen, Aberdeen AB25 2ZD, UK
A R T I C L E I N F O
Article history:
Available online 12 November 2010
Keywords:
Th17
C-type lectin
Syk kinase
Fungi
Mycobacteria
A B S T R A C T
Th17 cells are a recently discovered subset of T helper cells characterised by the release of IL-17, and are
thought tobe important formobilizationof immune responsesagainstmicrobial pathogens,butwhichalso
contribute to thedevelopment of autoimmunediseases. The identiﬁcationof C-type lectin receptorswhich
are capable of regulating the balance between Th1 and Th17 responses has been of particular recent
interest,which they control, inpart, though the releaseofTh17 inducingcytokines.Manyof these receptors
recognise fungi, and other pathogens, and play key roles in driving the development of protective anti-
microbial immunity. Here we will review the C-type lectins that have been linked to Th17 type responses
and will brieﬂy examine the role of Th17 responses in murine and human anti-fungal immunity.
 2010 Elsevier Ltd.
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Effector T helper cells were originally classiﬁed as Th1 or Th2
cells, characterised largely by the production of IFNg or IL-4,
respectively. More recently, a third subset of effector cell has been
identiﬁed, the Th17 cell, which are characterised by the production
of IL-17. The inductionofTh17celldifferentiationhasbeenanareaof
considerable focus, and it is now appreciated that the development
of these cells involves cytokines including TGF-b, IL-1b, IL-6, IL-21,
and IL-23, and transcription factors including retinoic acid receptor-
related orphan nuclear receptors (ROR) a and gt [1]. However, the
actual involvement of cytokines, such as IL-23 and TGF-b, in the
differentiation of Th17 cells has been controversial, as has the
relatedness between human and mouse Th17 cells, although many
of these controversies are starting to be resolved.
In addition to IL-17A and IL-17F, Th17 cells produce a variety of
other cytokines, such as IL-21 and IL-22 for example, all of which
are capable of inducing a variety of inﬂammatory and anti-
microbial responses in other cell types, including myeloid and
epithelial cells [1]. Consequently, Th17 responses have been
implicated in driving protective immune responses against a
variety of microbes, including several bacterial and fungal
pathogens [2]. However, the inﬂammatory effects of these
responses have also been implicated in the development of
autoimmune diseases, such as experimental autoimmune enceph-
alomyelitis [1]. Thus the protective anti-microbial effects of Th17
immunity can also contribute to pathology, perhaps explaining
some of the controversy surrounding the role of these responses in
murine models of fungal infection (discussed later).* Corresponding author.
E-mail address: gordon.brown@abdn.ac.uk (G.D. Brown).
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Open access under CC BY license.Another area of interest has been the identiﬁcation of the
pattern recognition receptors (PRRs) and intracellular signalling
pathways in antigen presenting cells (APCs) which drive the
development of Th17 immunity. One group of PRRs which appear
to have an emerging role in these types of responses are the C-type
lectin receptors (CLRs), and particularly those that signal via the
Syk/CARD9 pathway. As we shall see, many of these receptors are
involved in fungal and bacterial recognition, and are capable of
directly stimulating the development of adaptive immune
responses. Thus these receptors act as archetypical PRRs, with
functions analogous to those of the Toll-like receptor (TLR) family.
In this review, we will examine each of the CLRs which have been
implicated in Th17 immunity, andwewill also brieﬂy discusswhat
is known about the role of this type of adaptive response in anti-
fungal immunity.
2. C-type lectins and Th17 responses
The C-type lectin-like receptors (CLRs) are a diverse family of
proteins that are characterised by the presence of one or more C-
type lectin-like domains (CTLDs). The CTLD is normally involved in
ligand recognition and consists of a distinct protein fold that is
created by disulphide bridges between conserved cysteine
residues [3]. The CLRs are found as both soluble and membrane
bound proteins and, although originally deﬁned as carbohydrate
binding proteins, are now known to be able to recognise a wide
variety of other exogenous pathogen associated molecular
patterns (PAMPs) and endogenous ligands, including proteins
and lipids. Some of the membrane bound receptors are capable of
triggering intracellular signalling; either directly through integral
cytoplasmic signalling motifs, or indirectly, through association
with signalling adaptor molecules, such as the Fcg chain (see Ref.
[4] for a review). The intracellular signalling pathways induced by
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Fig. 1. Cartoon representation of the roles of CLRs during the development of Th17 responses.
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normally occurs with receptors containing immuno-receptor
tyrosine-based inhibitory motifs or ITIMs), or these receptors
can trigger cellular activation (through immuno-receptor tyrosine-
based activation motifs or ITAMs), resulting in the stimulation of
various cellular responses, including the induction of gene
expression. Based on their phylogeny and domain organization,
CLRs have been divided into 17 families [5], but of interest are
members of the group II, V and VI receptors which have been
implicated in Th17-type responses including Dectin-1, Dectin-2,
Mincle, DC-SIGN, CLEC-1, and CD161 (a summary of the roles and
ligands of these various receptors is shown in Fig. 1 and Table 1).
Most of these receptors have also been implicated in anti-microbial
immunity.Table 1
C-type lectin receptors (CLRs), their ligands, and their role in the development of Th17
CLR Ligands Pathogens reco
Dectin-1 Exogenous: b1,3-glucan Fungi: Candida,
Coccidioides, Sa
Endogenous: T-cell ligand? Bacteria: mycob
Dectin-2 Exogenous: High mannose structures Fungi: Cryptoco
Microsporum, T
Histoplasma
Endogenous: T-cell ligand? Bacteria: mycob
Mannose receptor Exogenous: terminal mannose, fucose,
N-acetyl glucosamine, sulphated sugars
Fungi: Candida,
Endogenous: Various e.g. glycoprotein
receptors, hormones, lysosomal enzymes
Bacteria: mycob
Streptococcus
Virus: Dengue,
Protozoa: Leish
Mincle Exogenous: a-mannan, mycobacterial
cord factor
Fungi: Candida,
Endogenous: SAP130
DC-SIGN Exogenous: high mannose and fucosylated
structures.
Fungi: Candida,
Endogenous: Various e.g. intercellular
adhesion molecule
(ICAM)-2 and 3, Lewis-x
Bacteria: mycob
Virus: HIV
CLEC-1 Exogenous: ? ?
Endogenous: T-cell ligand?
CD161 Exogenous: ? ?
Endogenous: PILAR, CLEC2D2.1. Dectin-1 (Clec7a)
Dectin-1 is a type II transmembrane protein that is expressed
predominantly by myeloid cells (monocytes/macrophages, den-
dritic cells and neutrophils), although the receptor is expressed on
some other cell types, including various populations of lympho-
cytes [6]. The highest levels of Dectin-1 expression are on
inﬂammatory cells and on cells at portals of pathogen entry,
and the levels of this receptor can be signiﬁcantly modulated by
cellular maturation, cytokines and other biological response
modiﬁers [6]. Notably, expression of Dectin-1 can be induced on
other cell types, including mucosal epithelium [7].
Dectin-1 consists of a single extracellular CTLD, linked by a stalk
and transmembrane region to a cytoplasmic tail containing anresponses.
gnised Role in Th17 cell responses
Aspergillus, Pneumocystis,
ccharomyces
Promotes Th17 responses to fungi
and mycobacteria
acteria
ccus, Candida, Saccharomyces,
richophyton, Paracoccidioides,
Promotes Th17 responses to fungi
acteria
Cryptococcus, Pneumocystis Unclear: suppresses Th17 responses
to mycobacteria, but induces these
responses to Candida.
acteria, Klebsiella,
HIV
mania
Saccharomyces, Malassezia Promotes Th17 responses to
mycobacteria (probably also fungi)
Chrysosporium, Aspergillus Unclear: but may suppress Th17
responses.
acteria
Unclear: but may suppress Th17 responses?
Th17 marker
T-cell proliferation?
Cell migration?
Regulation of cytokine production?
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exists as two major isoforms, generated by alternative splicing,
that differ by the inclusion of the extracellular stalk region and
which possess slight functional differences [6]. Dectin-1 speciﬁ-
cally recognises b1,3-linked glucans, carbohydrates found in the
cell walls of fungi, and in plants and some bacteria. Dectin-1
recognises several fungal species, including a number of human
pathogens such as Candida, Aspergillus, Pneumocystis and Cocci-
dioides, and plays an important role in host defence against these
pathogens [6,8,9]. Dectin-1 can also recognisemycobacteria and an
endogenous molecule on T-cells, but the identity of the ligand(s)
involved is unknown [6].
Ligand binding to Dectin-1 can induce a variety of cellular
responses including ligand uptake by endocytosis and phagocyto-
sis, cellular maturation, the respiratory burst, the production of
arachadonic acid metabolites, and the production of numerous
cytokines and chemokines, including IL-2, IL-10, CXCL2, TNF, IL-1b,
IL-6 and IL-23 [6]. Dectin-1 can also interact with MyD88-coupled
Toll-like receptors to synergistically induce the production of
cytokines, including IL-6 and IL-23, but these interactions also
result in the down regulation of IL-12 which is likely to contribute
to the development of Th17 responses (see below) [10,11].
Signalling from Dectin-1 is mediated by the cytoplasmic ITAM-
like motif and involves several downstream pathways, including
those mediated through Syk/CARD9 and Raf-1 kinase [6].[()TD$FIG]Fig. 2. Cartoon representation of the structures and known signalling pathwDectin-1 is also able to direct the development of adaptive
immunity. Stimulation of Dectin-1 on antigen presenting cells
(APCs) using highly puriﬁed b-glucans has been shown to induce
the differentiation of Th17 and Th1 CD4+ T-cells and drive the
development of antibody and CD8+ T-cell responses [12–14]. How
Dectin-1 actually drives the development of Th17 responses is still
unclear, although it requires both the Syk/CARD9 and the Raf-1
kinase signalling pathways, phospholipase C-g2, and is likely to
stem from the ability of Dectin-1 to stimulate (IL-1b, IL-6 and IL-
23) and inhibit (IL-12) the production of cytokines important in
shaping the development of these responses [11,14,15]. Stimula-
tion of Dectin-1 on APCs, and the generation of IL-23, has also been
shown to be capable of driving the conversion of selected
populations of Treg cells into IL-17 producing T-cells [16]. More
recently, the direct stimulation of Dectin-1 ongd T-cells, which are
thought to contribute to early innate responses, induced the
production of IL-17 from these cells; a response which could be
substantially enhanced in the presence of IL-23 [17].
Several studies have suggested a role for Dectin-1 in driving IL-17
responses during fungal infection. In humans, a polymorphism of
Dectin-1 has been identiﬁed which introduces a premature stop
codon (Tyr238X) that prevents the expression of this receptor at the
cell surface [9]. Individuals homozygous for this polymorphism are
susceptible to mucocutaneous fungal infections and have defective
production of cytokines, including IL-17, in response to fungi [9].ays that are employed by the various CLRs involved in Th17 responses.
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tion, have been associatedwith susceptibility to invasive Aspergillo-
sis in stem cell transplant patients [18], and it was also associated
with a decreased incidence of graft versus host disease that was
linkedwithCandida colonization in thesepatients [19]. Interestingly,
in murine models, Dectin-1 does not appear to play a major role in
driving Th17 immunity in response to C. albicans [12], however this
receptor was involved in generating protective IL-17 responses
during experimental pulmonary infection with A. fumigatus [8].
In addition to fungi, Dectin-1 has been implicated in the
development of adaptive responses toMycobacterium tuberculosis.
Several studies have suggested that Dectin-1 is involved in
mycobacterial uptake and the induction of cytokines, such as IL-
12, IL-23, IL-1b and IL-6, in response to these organisms [6,20].
Furthermore, recognition of mycobacteria by Dectin-1 on human
APC in vitrowas shown to promote the generation of Th1 and Th17
CD4+ lymphocytes, and the receptor may also be involved in the
mycobacterial-mediated stimulation of IL-17 from gd T-cells
[17,20,21].
2.2. Dectin-2 (Clec-4n)
Dectin-2 is a type II transmembrane receptor expressed
predominantly on tissue macrophages, DCs, and inﬂammatory
monocytes [22]. The receptor possess a classical sugar-binding CTLD
which recognises high mannose structures in a Ca2+ dependent
manner, through which it recognises a variety of pathogens
including capsule-deﬁcient Cryptococcus neoformans, Candida albi-
cans, Saccharomyces cerevisiae, M. tuberculosis, Microsporum audou-
nii, Trichophyton rubrum, Paracoccidioides brasiliensis and
Histoplasma capsulatum [23,24]. Dectin-2 also recognises allergens
from house dust mites and fungi, and plays a role in UV-induced
tolerance through the recognition of an unidentiﬁed endogenous
ligand on CD4+ CD25+ T-cells [25,26]. Although the receptor has a
short cytoplasmic tail which lacks traditional signalling motifs,
Dectin-2 associateswith the ITAM-containing FcRg adaptor and can
trigger intracellular signalling through the Syk-CARD9 pathway to
induce a variety of cellular responses, including the production of
ecosanoids, cytokines and chemokines (Fig. 2) [24,26–30].
Two recent studies, focussed on characterising the role ofDectin-
2 in the host response to C. albicans, have provided the ﬁrst evidence
of a role for this receptor in the induction of Th17 responses. In these
studies, Dectin-2 was shown to contribute to the induction of
cytokines, including TNF, IL-6, IL-1b and IL-23, following stimula-
tion of DC with fungal particles. Importantly, Dectin-2 signalling
through the Syk/CARD9 pathway was shown to play a substantial
role in the development of Th17 and Th1 responses upon C. albicans
infection inmice, although the latter response also required Dectin-
1 [28,29]. Using gene-deﬁcient mice, Saijo et al. were additionally
able to show that Dectin-2, which recognises fungal a-mannans,
was essential for resistance to infection with C. albicans [28]. Based
on these results, Robinson et al. have proposed that Dectin-2 and
Dectin-1 account for nearly all of the Syk/CARD9-dependent
signalling induced in response to these fungal pathogens [29].
2.3. Mannose receptor
The macrophage mannose receptor (MR; CD206) is a type I
transmembrane protein which possess eight extracellular CTLDs
and a short cytoplasmic tail which lacks classical signalling motifs
(Fig. 2). Although the majority of the MR is located intracellularly,
within the endocytic pathway, a soluble form of the receptor is also
shed into the serum. The MR is expressed by macrophages, some
DC, as well as a variety of other cells and tissues, including hepatic
and lymphatic endothelia [31,32]. The MR can bind terminal
mannose, fucose or N-acetyl glucosamine and consequentlyrecognises a wide variety of endogenous and exogenous ligands,
including several bacterial, viral and fungal pathogens (such as C.
neoformans, C. albicans and Pneumocystis carinii) [32].
The MR has been shown to induce a variety of cellular
responses, but the molecular mechanisms responsible for trans-
ducing the intracellular signals from this receptor are unclear. The
recognition of fungi by this receptor, which may only occur in the
phagosome following fungal uptake, has been shown to promote
the production of a number of cytokines, such TNF, GM-CSF, IL-12,
IL-8, IL-6, and IL-1b, although there is also evidence that the MR
can inhibit the production of certain cytokines, including TNF [32–
34]. Although the MR plays a clear role in homeostasis, its role in
anti-microbial immunity is still unclearwithMR deﬁcientmice not
showing signiﬁcant alterations in immunity to C. albicans or P.
carinii [35–37]. However these animals were found to be more
susceptible to infection with C. neoformans, which resulted from
defective induction of protective CD4+ T-cell responses [38].
Using in vitro assays with human PBMCs, Netea et al. recently
demonstrated that stimulation of the MR with Candida or puriﬁed
Candidamannan was able to induce signiﬁcant levels of IL-17 [39].
This response was not a direct mitogenic stimulation of T-cells, as
it required APCs, and both Dectin-1 and TLR2 were able to amplify
these responses. This response was speciﬁc for Candida, as mannan
isolated from S. cerevisiae had no effect [39]. In contrast to these
results, however, another study demonstrated that stimulation of
the MR could suppress Th17 responses induced by mycobacteria
[20]. Understanding the signalling mechanisms utilised by the MR,
and the effects of collaboration with different PRRs, are clearly
issues that need to be addressed if the role of this receptor is to be
fully understood.
2.4. Mincle (Clec4e)
Macrophage inducible C-type lectin (Mincle) is a type II
transmembrane protein that is primarily expressed by activated
macrophages, and probably also by DCs [40,41]. Like Dectin-2,
Mincle possesses a single extracellular CTLD, a short cytoplasmic
tail, and associates with the adaptor FcRg to trigger intracellular
signalling through the Syk/CARD9 pathway [42] (Fig. 2). Mincle
recognises a variety of endogenous and exogenous ligands, such as
necrotic cells, mycobacteria and certain fungi, including Candida,
Saccharomyces and Malassezia (although the receptor may
preferentially recognise the latter fungal species) [42–44]. Many
of the ligands involved in these interactions have been identiﬁed
and include fungal a-mannan, mycobacterial cord factor (treha-
lose-dimycolate as well as the synthetic analogue trehalose-
dibehenate), and the small nuclear ribonucleoprotein SAP130
[42,44–46]. Upon recognition of these ligands, Mincle has been
shown to induce a variety of cellular responses, including the
induction of cytokines such as TNF, MIP-2, KC, IL-10 and IL-6.
Mincle knockout mice show increased susceptibility to infections
with Candida, and blocking Mincle function with antibodies in vivo
has been found to reduce neutrophil recruitment and inﬂamma-
tory cytokine production in response to necrotic cell death [42,43].
Of relevance here is the ability of Mincle to mediate immune
responses to trehalose-dimycolate (TDM) and trehalose-dibehenate
(TDB). TDM, which has potent inﬂammatory activity and is thought
to be a key driver of pathogenesis during tuberculosis, and its less
toxic analogue TDB, have been shown to be useful adjuvants for
mycobacterial subunit vaccines in driving the development of
protective Th1 and Th17 responses [41,47]. Recent data has shown
thatMinclemediates all of the responses toTDMandTDB,withmice
deﬁcient in Mincle (or FcRg chain) losing the ability to induce Th1
and Th17 responses following TDB/antigen immunization [45,46].
Thus like the other Syk-coupled C-type lectins described above,
Mincle is able to direct the development of Th17 responses, and
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also contribute to the development of these responses during fungal
infection.
2.5. DC-SIGN
Human DC-SIGN (CD209) is a type II transmembrane protein
possessing a single extracellular CTLD, and a cytoplasmic tail
containing internalization motifs (Fig. 2). DC-SIGN is expressed as a
tetramer, due to interactionsbetween the extracellular stalk regions
of the monomers, and the receptor is expressed primarily by
immature DC, but it is also found on selected macrophages and
endothelial cells [48–50]. Mice express eight orthologs of this
receptor, which differ slightly in their structure and expression
proﬁles [51,52]. DC-SIGN recognises carbohydrates, including high-
mannose and fucosylated structures, enabling it to recognise awide
variety of pathogens including mycobacteria and several fungal
pathogens, such as Candida species, conidia of A. fumigatus,
Chrysosporium tropicum, and possibly also C. neoformans [51,53–55].
Although the exact mechanisms are still unclear, DC-SIGN is
able to induce intracellular signalling resulting in cellular
responses, such as phagocytosis [55]. DC-SIGN signalling is
mediated, in part, through the Raf-1 kinase pathway, and can
modulate cytokine production induced through other PRRs,
including the TLRs, although the receptor does not appear to be
able to directly induce the production of cytokines [56]. The
signalling induced by DC-SIGN depends on the nature of the
carbohydrate ligand, resulting in the stimulation or repression of a
number of cytokines including IL-10, IL-12 and IL-6 [56,57].
Indeed, a recent study has demonstrated that stimulation of DC-
SIGN using deﬁned ligands could inhibit the production of
cytokines, including IL-1b, IL-23 and TNF, that were induced by
M. tuberculosis or beta-glucan in human DCs, and that this led to a
repression of Th17 responses [20]. Thus, although only demon-
strated in one study to date, these results suggest that signalling
from DC-SIGN can modulate the development of Th17 responses.
2.6. CLEC-1 (CLEC-1A)
CLEC-1 is a relatively poorly characterisedmember of theDectin-
1 cluster of C-type lectins, and is expressed by endothelial cells, DC
andother tissuemyeloidcells,butnotbymonocytes,granulocytes,B,
T orNK cells in peripheral blood [58,59]. This type II transmembrane
receptor is structurally similar to Dectin-1, although it does not
contain any canonical signalling motifs, and may associate with an
adaptor for expression at the cell surface [58]. However, the
cytoplasmic tail does possess a single tyrosine residue, which may
be able to induce intracellular signalling (Fig. 2). Expression of CLEC-
1was found to be down-regulated by inﬂammatory stimuli, such as
LPSor IFNg, but upregulatedby immunosuppressive cytokines, such
as IL-10 and TGF-b [60]. Interestingly, in rodentmodels, CLEC-1was
found to be upregulated in tolerated allografts, and this was
associated with low levels of IL-17 and the presence of CD4+CD25+
Treg cells at the graft site. In vitro assays demonstrated that CLEC-1
expression was increased on endothelial cells upon contact with
CD4+CD25+ Treg cells, and that loss of CLEC-1 expression from DC
(using siRNA) enhanced the development of Th17 cells, while
reducing Foxp3 expression, in MLRs [60]. Overall these results
suggest that CLEC-1 plays a role in regulating the development of
Th17 cells, but more data is need to fully understand the role and
underlying mechanisms utilised by this receptor.
2.7. CD161
CD161 (NKRP1a) is a type II transmembrane receptor that
consists of a single extracellular CTLD and a cytoplasmic tail thatcontains an atypical ITIM-like motif [61] (Fig. 2). The receptor is
expressed by subsets of NK, NKT and T-cells, and has also been
detected on monocytes and DC [61–63]. CD161 has been shown to
recognise a number of ligands including carbohydrates, lectin-like
transcript-1 (LLT1, CLEC2D), and proliferation-induced lympho-
cyte-associated receptor (PILAR) [64–66]. The role of CD161 is still
unclear, but it has been shown to be capable of regulating NK cell
cytolysis, trans-endothelial migration, and the proliferation of
immature thymocytes, T-cells and NKT cells [62,64,65,67,68]. The
receptor can also modulate the production of cytokines, including
TNF, IL-1b, IFNg, IL-4, IL-12, in various CD161+ myeloid and
lymphoid cells [62,69]. How CD161 mediates these effects is still
largely unknown, although its effects on T-cell proliferation were
shown to involve interactionswith PILAR, and signalling in NK cells
has been shown to involve activation of acid sphingomyelinase
[66,70].
Of relevance here is the use of CD161 as a marker of IL-17
producinghuman T-cells. Originally demonstrated to deﬁne subsets
of CD4+ and CD8+ human T-cells with different functional activities,
CD161 was subsequently shown to be highly upregulated in IL-17
producing T-cells, and in the precursor cells found in the umbilical
cord and newborn thymus [71,72]. This led to the proposal that
CD161 was a speciﬁc marker for Th17 cells, and subsequent studies
have shown that this receptor is indeed expressed on all human IL-
17 producing T-cell subsets, including those implicated in intestinal
inﬂammation and in chronic inﬂammation induced by viral
infection [72–75]. Interestingly, the mouse homologue (NK1.1)
has not been found on IL-17 producing T-cells, which has
contributed, at least in part, to the speculation that murine Th17
cells are different to those found in humans [76].
Despite the use of this receptor as a Th17 T-cell marker, its
function on these cells is still unclear. Stimulation of this receptor
on Th17 cells using antibodies had no effect on proliferation or
cytokine production [72]. Given that Th17 cells can target speciﬁc
tissues through the expression of chemokine receptors, such as
CCR6, Cosmi et al. have proposed that CD161may play a role in the
trans-endothelial migration of these cells [72–74]. Clearly there is
still much to be learned about the function of CD161 and its
involvement in these responses.
3. Th17 in anti-fungal defence
Protective immunity to most fungal infections requires
adaptive immune responses involving CD4+ T-cells, as evidenced
by the susceptibility of HIV-patients to infections with fungal
pathogens such as Candida and Cryptococcus. Historically, protec-
tion from fungal infections was thought to require Th1 immunity,
while Th2 responses promoted susceptibility [77]. More recently,
Th17 responses have also been implicated in anti-fungal immunity
and, as we discuss below, data from both human and mouse have
suggested that these responses are required for protection [78,79].
However, the protection mediated by these responses may be
limited to particular sites (such as the oral mucosa) and there is
evidence that they may also have detrimental effects during
infection.
3.1. Human Th17-related fungal diseases
In the last few years several genetic causes for alterations in
Th17 immunity have been identiﬁed which are linked with defects
in anti-fungal immunity, including mutations in STAT3 (Hyper IgE
syndrome; HIES), AIRE (autoimmune polyendrocrinopathy with
candidiasis and ectodermal dystrophy; APECED), Dectin-1 (which
was discussed above) and CARD9 [80]. There are also reports of
patientswith othermutations, such as those resulting in deﬁciency
in IL-12p40 and IL-12Rb1, which result in reduced levels of Th17
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less well characterised [80,81]. In all cases, most affected
individuals suffer from chronic mucocutaneous candidiasis
(CMC); a heterogenous group of diseases in which patients suffer
from persistent or recurrent Candida infections of the mucous
membranes, skin and nails (onchomycosis).
3.1.1. Hyper IgE syndrome (HIES)
Autosomal dominant-HIES, or Job’s syndrome, is a complex
immunodeﬁciency characterised by high serum IgE levels, atopic
dermatitis, susceptibility to staphylococcal and fungal infections,
and a variety of other non-immunological disorders, including
bone and dental abnormalities. More than 80% of these patients
suffer from CMC, but infections with other fungi, including
Aspergillus, Cryptococcus and Pneumocystis have also been
reported [82]. The major underlying defect was identiﬁed as a
loss of function of signal transducer and activator of transcription
3 (STAT3), a result of dominant negative mutations in various
regions of the protein [83,84]. STAT3 is activated following
stimulation with several key cytokines involved in Th17
differentiation, including IL-6, IL-21 and IL-23, and it is required
for the induction of RORgt, downregulation of FoxP3 in Treg cells,
and expression of IL-23R and IL-17 itself [85]. Several studies have
demonstrated that T-cells from patients suffering from HIES did
not produce IL-17 andwere unable to differentiate into Th17 cells
(for examples see Refs. [81,86,87]).
3.1.2. Autoimmune polyendrocrinopathy with candidiasis and
ectodermal dystrophy (APECED)
APECED, also known as autoimmune polyendocrine type I
syndrome (APS-1), is a rare autosomal recessive disease char-
acterised by an autoimmune-mediated destruction of various
endocrine glands, resulting particularly in hypoparathyroidism
and adrenal insufﬁciency, and a host of other abnormalities,
including ectodermal dystrophies [88]. Another characteristic of
thedisease, andoftenoneof theﬁrst indicators, is CMC. Themajority
of patients with this disease (>95%) have been found to have
mutations in the autoimmune regulator (AIRE) genewhich render it
non-functional [89,90]. AIRE is involved in central tolerance, by
controlling the production of self-antigens in the thymus and
peripheral lymphoid organs, and loss of function of this regulator
gives rise to the development of autoimmunity [88]. Two recent
studies have demonstrated that these patients make neutralizing
autoantibodies to Th17 cytokines, including IL-17A, IL-17F and IL-
22, and the loss of these cytokines correlates with the increased
susceptibility to CMC [91,92]. The production of similar autoanti-
bodies was also found to correlatewith the rare occurrences of CMC
infection that are observed in certain thymoma patients [91].
3.1.3. CARD9 deﬁciency
CARD9 (caspase recruitment domain-containing protein 9) is a
key signalling adaptor inmyeloid cells, that forms a complexwithB-
cell lymphoma 10 (BCL10) and mucosa-associated lymphoid tissue
(MALT1) to transduce signals that activate mitogen-activated
protein kinases (MAPK) and nuclear factor (NF-kB) [93]. CARD9
mediates the signalling downstream of Syk kinase, triggered from
the ITAM-coupled receptors includingMincle, Dectin-2 and Dectin-
1 (discussed above; see Fig. 2), leading ultimately to the production
of numerous cytokines and chemokines and the induction of Th17
responses [12]. In mice, CARD9 has been shown to play an essential
role in anti-fungal and anti-bacterial immunity [93–95]. In humans,
a CARD9mutation has recently been identiﬁedwhich gives rise to a
premature stop codon (Q295X) [96]. Individuals homozygous for
this mutation suffer from CMC and other dematophyte infections,
and a number of patients also had invasive candidiasis (some of
which died from these infections). Correlating with defectivesignalling through the CARD9 pathway, the affected individuals
hadamuch lowerproportionofTh17cells thanhealthycontrols, and
in vitro experiments demonstrated that cells possessing this
mutation were signiﬁcantly impaired in their ability to induce
inﬂammatory responses to fungal particles [96].
3.2. Mouse models
The human studies discussed above strongly suggest that Th17
responses are protective, but the data to date are only correlative.
However, data from studies using knockout mouse models are not
much better, and the role of Th17 responses in anti-fungal murine
immunity (mostly with C. albicans) is still somewhat controversial.
On the one hand, Th17 responses have been shown to confer
protection in both systemic and oral mucosal models, which has
been ascribed to the beneﬁcial effects of IL-17 on the induction of
anti-microbial effectors and neutrophil recruitment [78,97,98].
Similar protective effects of Th17 responses have also been shown
for Cryptococcus neoformans and P. carinii [99,100]. On the other
hand, different groups have reported that these responses either do
not play a role (systemic infection), or are actually detrimental to
the host (gastric mucosal and systemic infections), as a result of
inappropriate IL-17-mediated neutrophil activation and resultant
tissue pathology [101,102]. There are also similar contradictory
data on the role of IL-22 [98,103]. The reasons for these differences
are still unclear, but may be related to the choice of model (e.g.:
oral versus gastric infection, which may suggest tissue speciﬁc
protective effects of Th17 responses), mouse background (e.g.:
Balb/C or C57BL/6) or knockout tested (e.g. IL-17A, IL-17R, etc.).
These differences may also be a result of diverse fungal strains
being used, which are recognised by different PRRs and which can
also actively suppress Th17 responses [104,105].
4. Conclusions
Since the identiﬁcation of Th17 cells much progress has been
made in understanding the role and mechanisms involved in
establishing this type of adaptive immunity. The C-type lectins
have been of particular interest, as they have been implicated in
inducing and modulating these types of responses. However, as
highlighted during this review, there is still much we do not know
and many controversies still to resolve, particularly with the
mouse models of fungal infection. Gaining a better understanding
of the functions of these C-type lectins, and their involvement in
Th17 responses, should aid in the future development of novel
vaccination strategies and may suggest avenues to enhance
protective immune responses to infection.
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